These findings further suggest that targeting transcription factors such as STAT3 has the potential to revolutionize the pharmaceutical landscape and provide improved options for combination therapy strategies in EGFR-mutant NSCLC patients. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.